Xiang Rong, Fan Liang-Liang, Lin Min-Jie, Li Jing-Jing, Shi Xiang-Yu, Jin Jie-Yuan, Liu Yu-Xing, Chen Ya-Qin, Xia Kun, Zhao Shui-Ping
The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, Changsha 410013, China; Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, Changsha 410013, China.
Atherosclerosis. 2017 Mar;258:84-88. doi: 10.1016/j.atherosclerosis.2017.02.007. Epub 2017 Feb 11.
Familial hypercholesterolemia (FH) is the most common and severe autosomal dominant lipid metabolism dysfunction, which causes xanthoma, atherosclerosis and coronary heart disease. Earlier studies showed that mutations in LDLR, APOB and PCSK9 cause FH. Although more than 75% of the population in Europe has been scrutinized for FH-causing mutations, the genetic diagnosis proportion among Chinese people remains very low (less than 0.5%). The aim of this study was to perform a survey and mutation detection among the Chinese population.
219 FH patients from the central south region of China were enrolled. After extracting DNA from circulating lymphocytes, we used direct DNA sequencing to screen each exon of LDLR, APOB and PCSK9. All detected variants were predicted by Mutationtaster, Polyphen-2 and SIFT to assess their effects.
In total, 43 mutations were identified from 158 FH patients. Among them, 11 novel mutations were found, including seven LDLR mutations, two APOB mutations and two PCSK9 mutations. Moreover, five common mutations in LDLR were detected. We geographically marked their distributions on the map of China.
The spectrum of FH-causing mutations in the Chinese population is refined and expanded. Along with future studies, our study provides the necessary data as the foundation for the characterization of the allele frequency distribution in the Chinese population. The identification of more LDLR, APOB and PCSK9 novel mutations may expand the spectrum of FH-causing mutations and contribute to the genetic diagnosis and counseling of FH patients.
家族性高胆固醇血症(FH)是最常见且严重的常染色体显性脂质代谢功能障碍,可导致黄瘤、动脉粥样硬化和冠心病。早期研究表明,低密度脂蛋白受体(LDLR)、载脂蛋白B(APOB)和前蛋白转化酶枯草溶菌素9(PCSK9)的突变会导致FH。尽管欧洲超过75%的人口已接受FH致病突变筛查,但中国人中的基因诊断比例仍然很低(不到0.5%)。本研究的目的是对中国人群进行调查并检测突变。
招募了来自中国中南地区的219例FH患者。从循环淋巴细胞中提取DNA后,我们使用直接DNA测序法筛查LDLR、APOB和PCSK9的每个外显子。所有检测到的变异均通过Mutationtaster、Polyphen-2和SIFT进行预测,以评估其影响。
总共从158例FH患者中鉴定出43个突变。其中,发现了11个新突变,包括7个LDLR突变、2个APOB突变和2个PCSK9突变。此外,还检测到LDLR中的5个常见突变。我们在中国地图上标记了它们的地理分布。
中国人群中FH致病突变谱得到了细化和扩展。随着未来的研究,我们的研究提供了必要的数据,作为中国人群等位基因频率分布特征化的基础。更多LDLR、APOB和PCSK9新突变的鉴定可能会扩大FH致病突变谱,并有助于FH患者的基因诊断和咨询。